AUGMENTATION OF VASCULAR ENDOTHELIAL BARRIER FUNCTION BY HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN

被引:0
|
作者
BANNON, PG
KIM, MJ
DEAN, RT
DAWES, J
机构
[1] CRC BIOPHARMACEUT RES, DARLINGHURST, NSW 2010, AUSTRALIA
[2] HEART RES INST, APPL RES GRP, SYDNEY, NSW, AUSTRALIA
[3] HEART RES INST, CELL BIOL GRP, SYDNEY, NSW, AUSTRALIA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glycosaminoglycans (GAGs) are an important component of endothelial barrier function. Early passage human umbilical vein endothelial cells were grown to confluence on transparent micropore filters and barrier function assessed as transendothelial electrical resistance (TEER) and permeability to albumin and sucrose. Unfractionated heparin and the LMW heparin Clexane decreased endothelial permeability to both sucrose and albumin and increased TEER. Chondroitin 6-sulphate also augmented barrier function, but other GAGs had no effect. Interleukin-1 increased permeability to albumin and sucrose and decreased TEER. Although heparin attenuated the effect of IL-1 on TEER and sucrose permeability, it could not restore the barrier to albumin transfer. Denuded endothelial matrix presented a negligible barrier, which was not enhanced by heparin. When sulphation of endogenous GAGs was inhibited by chlorate, barrier function was compromised and was not restored by exogenous heparin. Thus heparin enhances the barrier function of resting endothelium, but cannot completely overcome the increased permeability resulting from exposure to IL-1 or substitute for endogenous GAGs.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 50 条
  • [31] Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism
    Pineo, GF
    Hull, RD
    BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (03): : 621 - 637
  • [32] PHARMACOKINETICS OF A LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH STANDARD HEPARIN
    MATZSCH, T
    BERGQVIST, D
    HEDNER, U
    OSTERGAARD, P
    THROMBOSIS RESEARCH, 1986, : 118 - 118
  • [33] Localization of heparin and low-molecular-weight heparin in the rat kidney
    Young, E
    Douros, V
    Podor, TJ
    Shaughnessy, SG
    Weitz, JI
    THROMBOSIS AND HAEMOSTASIS, 2004, 91 (05) : 927 - 934
  • [34] Hirudin versus heparin and low-molecular-weight heparin: And the winner is ...
    Hull, RD
    Pineo, GF
    Raskob, GE
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (03): : 171 - 174
  • [35] Effects of low-molecular-weight and unfractionated heparin on trophoblast function
    Quenby, S
    Mountfield, S
    Cartwright, JE
    Whitley, GSJ
    Vince, G
    OBSTETRICS AND GYNECOLOGY, 2004, 104 (02): : 354 - 361
  • [36] COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN VS UNFRACTIONATED HEPARIN IN GYNECOLOGICAL SURGERY .2. REDUCED DOSE OF LOW-MOLECULAR-WEIGHT HEPARIN
    BORSTAD, E
    URDAL, K
    HANDELAND, G
    ABILDGAARD, U
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1992, 71 (06) : 471 - 475
  • [37] Heparin and low-molecular-weight heparin therapy for venous thromboembolism: Will unfractionated heparin survive?
    Hull, RD
    Pineo, GF
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 : 11 - 23
  • [38] INDUCTION OF OSTEOPOROSIS IN RATS BY STANDARD HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN
    MATZSCH, T
    BERGQVIST, D
    HEDNER, U
    NILSSON, B
    OSTERGAARD, P
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 36 - 36
  • [39] BEHAVIOR OF UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN IN RAT ORGANISM
    KHLGATIAN, SV
    UMAROVA, BA
    SHAPIRO, FB
    STRUKOVA, SM
    DOKLADY AKADEMII NAUK SSSR, 1990, 313 (02): : 509 - 511
  • [40] HEPARIN LOW-MOLECULAR-WEIGHT HEPARIN AND TISSUE FACTOR PATHWAY INHIBITOR
    ABILDGAARD, U
    HAEMOSTASIS, 1993, 23 : 103 - 106